Origin Therapeutics Holdings (XCNQ:ORIG) Debt-to-Equity : 0.00 (As of Jun. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Origin Therapeutics Holdings Debt-to-Equity?

Origin Therapeutics Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was C$0.00 Mil. Origin Therapeutics Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was C$0.00 Mil. Origin Therapeutics Holdings's Total Stockholders Equity for the quarter that ended in Jun. 2023 was C$3.08 Mil. Origin Therapeutics Holdings's debt to equity for the quarter that ended in Jun. 2023 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Origin Therapeutics Holdings's Debt-to-Equity or its related term are showing as below:

XCNQ:ORIG's Debt-to-Equity is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 0.3
* Ranked among companies with meaningful Debt-to-Equity only.

Origin Therapeutics Holdings Debt-to-Equity Historical Data

The historical data trend for Origin Therapeutics Holdings's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Origin Therapeutics Holdings Debt-to-Equity Chart

Origin Therapeutics Holdings Annual Data

Trend

Sep21

Sep22

Debt-to-Equity

Origin Therapeutics Holdings Quarterly Data
	Mar21	Jun21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Debt-to-Equity	Get a 7-Day Free Trial				-	-	-	-	-

Competitive Comparison of Origin Therapeutics Holdings's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Origin Therapeutics Holdings's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Origin Therapeutics Holdings's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Origin Therapeutics Holdings's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Origin Therapeutics Holdings's Debt-to-Equity falls into.

Origin Therapeutics Holdings Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Origin Therapeutics Holdings's Debt to Equity Ratio for the fiscal year that ended in Sep. 2022 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	5.429
	=	0.00

Origin Therapeutics Holdings's Debt to Equity Ratio for the quarter that ended in Jun. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	3.081
	=	0.00

Origin Therapeutics Holdings (XCNQ:ORIG) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Origin Therapeutics Holdings Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Origin Therapeutics Holdings's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.